Arshad, M., Azad, A., Chan, P., Vigneswara, V., Feldinger, K., Nafi, S., . . . Kong, A. (2024). Neratinib could be effective as monotherapy or in combination with trastuzumab in HER2-low breast cancer cells and organoid models. Springer Nature [academic journals on nature.com].

Arshad, M., et al. Neratinib Could Be Effective as Monotherapy or in Combination with Trastuzumab in HER2-low Breast Cancer Cells and Organoid Models. Springer Nature [academic journals on nature.com], 2024.

Arshad, M., et al. Neratinib Could Be Effective as Monotherapy or in Combination with Trastuzumab in HER2-low Breast Cancer Cells and Organoid Models. Springer Nature [academic journals on nature.com], 2024.